Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Indivior strikes agreement with Actavis over patent dispute

(Sharecast News) - Indivior announced significant agreement in its ongoing patent dispute with Actavis Laboratories UT, a subsidiary of Teva Pharmaceuticals, on Wednesday. The FTSE 250 company said it had entered a settlement agreement with Actavis, resolving the patent disputes related to Actavis's Abbreviated New Drug Application (ANDA) for generic buprenorphine and naloxone sublingual film.

Under the settlement, Indivior granted Actavis a licence to its US patent to enable Actavis to launch the generic film products specified in its ANDA within the US.

However, the launch could not happen before 31 January 2025, unless the unexpired patent claims were determined to be invalid or unenforceable before that date in a final judicial decision.

At 0848 GMT, shares in Indivior were up 3.4% at 1,186p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Agronomics investee Solar Foods raises EUR 8m
(Sharecast News) - Cellular agriculture investor Agronomics announced on Friday that its portfolio company Solar Foods had raised an additional €8m through Finnish investment organiser Springvest.
Berenberg hikes target price on Greggs
(Sharecast News) - Analysts at Berenberg raised their target price on bakery chain Greggs from 3,550.0p to 3,990.0p on Friday as it noted that customer appeal had broadened as its market share was expanding.
Thousands of UK firms fighting for survival - Begbies Traynor
(Sharecast News) - More than half a million UK business are fighting for survival, according to an industry research published on Friday, weighed down by the weak economy.
Thruvision FY24 adjusted underlying losses widen
(Sharecast News) - Security technology business Thruvision said on Friday that adjusted underlying losses had widened in FY24 as revenues fell.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.